Profound Medical Announces Upcoming Investor Events

Rhea-AI Summary

Profound Medical (NASDAQ:PROF) will participate in two investor events in February 2026: the Lake Street Life-Sciences Invitational on Feb 4–5 in Scottsdale, AZ, and the BTIG 13th Annual MedTech conference on Feb 10–11 in Snowbird, UT. No webcasts will be available due to event formats.

TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February.

• Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4^th-5^th in Scottsdale, AZ.
• BTIG 13^th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference: The Company is scheduled to participate in a series of one-on-one meetings February 10^th-11^th in Snowbird, UT.

Due to the format of the events, no webcasts will be available.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

When will Profound Medical (PROF) attend the Lake Street Life-Sciences Invitational in 2026?

Profound Medical will attend on February 4–5, 2026 for one-on-one meetings. According to the company, participation consists of scheduled one-on-one investor meetings in Scottsdale, AZ and is not accompanied by a public webcast or group presentation.

What is Profound Medical (PROF) scheduled to do at the BTIG MedTech conference on Feb 10–11, 2026?

Profound Medical is scheduled for one-on-one investor meetings on February 10–11, 2026 in Snowbird, UT. According to the company, the format is individual meetings only and no webcast or public presentation will be provided.

Will Profound Medical (PROF) provide webcasts of its February 2026 investor meetings?

No, Profound Medical will not provide webcasts for these events. According to the company, both the Lake Street Invitational and the BTIG MedTech conference use a one-on-one format, so no webcast or group livestream will be available.

How can investors meet Profound Medical (PROF) management during the February 2026 events?

Investors may request one-on-one meetings scheduled by event organizers on the announced dates. According to the company, meetings are arranged through the Lake Street and BTIG conference programs, with sessions in Scottsdale on Feb 4–5 and Snowbird on Feb 10–11.

What locations will Profound Medical (PROF) visit for investor events in February 2026?

Profound Medical will visit Scottsdale, AZ and Snowbird, UT for investor events in February 2026. According to the company, the Lake Street Life-Sciences Invitational is in Scottsdale on Feb 4–5 and the BTIG MedTech conference is in Snowbird on Feb 10–11.